We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LHC Group (LHCG) Q1 Earnings Beat Estimates, Revenues Miss
Read MoreHide Full Article
LHC Group, Inc. reported first-quarter 2022 adjusted earnings per share (EPS) of $1.09, which beat the Zacks Consensus Estimate of $1.05 by 3.8%. The bottom line declined 21.6% year over year.
GAAP EPS was 64 cents in the quarter, down 41.8% on a year-over-year basis.
Revenue Details
The company reported net service revenues of $571.5 million in the quarter, which missed the Zacks Consensus Estimate by 0.3%. However, the top line improved 8.9% on a year-over-year basis.
Q1 Highlights
In the first quarter, total organic growth in home health admissions rose 1.6% year over year, while organic growth in hospice admissions rose 4%.
Home health service revenues were $387.9 million, up 3.8% year over year. Meanwhile, hospice services revenues amounted to $101.9 million, up 62.4%.
Strategic Update
On May 3, 2022, the company made an announcement that it has finalized a joint venture partnership for in-home services with Thomasville, GA-based Archbold Medical Center.
Margin Analysis
Gross profit in the quarter totaled $221.1 million, up 3%. Gross margin was 38.7%, which contracted 220 basis points (bps) on a year-over-year basis.
Operating profit was $35.5 million, down 30.5% from the prior-year quarter. Operating margin was 6.2%, down 350 bps.
Financial Position
LHC Group exited the first quarter with cash amounting to $7.7 million, down from $9.8 million sequentially.
Net cash used in operating activities at the end of the first quarter totaled $64.9 million against net cash provided in operating activities of $44.8 million in the year-ago quarter.
Wrapping Up
LHC Group exited the first quarter on a mixed note, wherein earnings beat the Zacks Consensus Estimate, but revenues missed the same. The company continues to gain from home health as well as hospice admissions that witnessed organic growth on a year-over-year basis. Robust revenue performance across home health and hospice is encouraging.
Nevertheless, contraction in both gross margin and operating margins is concerning. The year-over-year decline in the bottom line is a woe. A highly competitive home healthcare market remains a headwind.
Zacks Rank
LHC Group carries a Zacks Rank #3 (Hold).
Key Picks
Some better-ranked stocks in the broader medical space that have announced quarterly results are Omnicell, Inc. (OMCL - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Alkermes plc (ALKS - Free Report) .
Omnicell, carrying a Zacks Rank #2 (Buy), reported first-quarter 2022 adjusted EPS of 83 cents, which beat the Zacks Consensus Estimate by 16.9%. Revenues of $318.8 million outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Omnicell has an estimated long-term growth rate of 16%. OMCL's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 13.4%.
UnitedHealth, carrying a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 1.9%.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.7%.
Alkermes reported first-quarter 2022 adjusted EPS of 12 cents, which beat the Zacks Consensus Estimate of a penny. First-quarter revenues of $278.6 million outpaced the Zacks Consensus Estimate by 6.2%. It currently sports a Zacks Rank #1.
Alkermes has an estimated long-term growth rate of 25.1%. ALKS' earnings surpassed estimates in each of the trailing four quarters, the average surprise being 350.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
LHC Group (LHCG) Q1 Earnings Beat Estimates, Revenues Miss
LHC Group, Inc. reported first-quarter 2022 adjusted earnings per share (EPS) of $1.09, which beat the Zacks Consensus Estimate of $1.05 by 3.8%. The bottom line declined 21.6% year over year.
GAAP EPS was 64 cents in the quarter, down 41.8% on a year-over-year basis.
Revenue Details
The company reported net service revenues of $571.5 million in the quarter, which missed the Zacks Consensus Estimate by 0.3%. However, the top line improved 8.9% on a year-over-year basis.
Q1 Highlights
In the first quarter, total organic growth in home health admissions rose 1.6% year over year, while organic growth in hospice admissions rose 4%.
LHC Group, Inc. Price, Consensus and EPS Surprise
LHC Group, Inc. price-consensus-eps-surprise-chart | LHC Group, Inc. Quote
Home health service revenues were $387.9 million, up 3.8% year over year. Meanwhile, hospice services revenues amounted to $101.9 million, up 62.4%.
Strategic Update
On May 3, 2022, the company made an announcement that it has finalized a joint venture partnership for in-home services with Thomasville, GA-based Archbold Medical Center.
Margin Analysis
Gross profit in the quarter totaled $221.1 million, up 3%. Gross margin was 38.7%, which contracted 220 basis points (bps) on a year-over-year basis.
Operating profit was $35.5 million, down 30.5% from the prior-year quarter. Operating margin was 6.2%, down 350 bps.
Financial Position
LHC Group exited the first quarter with cash amounting to $7.7 million, down from $9.8 million sequentially.
Net cash used in operating activities at the end of the first quarter totaled $64.9 million against net cash provided in operating activities of $44.8 million in the year-ago quarter.
Wrapping Up
LHC Group exited the first quarter on a mixed note, wherein earnings beat the Zacks Consensus Estimate, but revenues missed the same. The company continues to gain from home health as well as hospice admissions that witnessed organic growth on a year-over-year basis. Robust revenue performance across home health and hospice is encouraging.
Nevertheless, contraction in both gross margin and operating margins is concerning. The year-over-year decline in the bottom line is a woe. A highly competitive home healthcare market remains a headwind.
Zacks Rank
LHC Group carries a Zacks Rank #3 (Hold).
Key Picks
Some better-ranked stocks in the broader medical space that have announced quarterly results are Omnicell, Inc. (OMCL - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Alkermes plc (ALKS - Free Report) .
Omnicell, carrying a Zacks Rank #2 (Buy), reported first-quarter 2022 adjusted EPS of 83 cents, which beat the Zacks Consensus Estimate by 16.9%. Revenues of $318.8 million outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Omnicell has an estimated long-term growth rate of 16%. OMCL's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 13.4%.
UnitedHealth, carrying a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 1.9%.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.7%.
Alkermes reported first-quarter 2022 adjusted EPS of 12 cents, which beat the Zacks Consensus Estimate of a penny. First-quarter revenues of $278.6 million outpaced the Zacks Consensus Estimate by 6.2%. It currently sports a Zacks Rank #1.
Alkermes has an estimated long-term growth rate of 25.1%. ALKS' earnings surpassed estimates in each of the trailing four quarters, the average surprise being 350.5%.